Organization | Kliniken Essen-Mitte, Germany

Kliniken Essen-Mitte, Germany Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial

2018

NCT03353831

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

Clinics Essen-Mitte, Breast Center | Georg Nilius, Prof DR med | KEM Essen | Evang. Kliniken Essen-Mitte gGmbH | KEM | Evang. Kliniken Essen-Mitte gGmbH | Kliniken Essen-Mitte, Germany

Active Ingredients

Drugs in Phase 3 Trials (5)

atezolizumab (Tecentriq) (1 trial)

bevacizumab (avastin) (2 trials)

carboplatin (paraplatin) (1 trial)

niraparib (zejula) (1 trial)

paclitaxel (taxol) (1 trial)

Drugs in Phase 2 Trials (3)

pembrolizumab (keytruda) (1 trial)

pertuzumab (perjeta) (1 trial)

trastuzumab (herceptin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Breast Neoplasms (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 3)

Ovarian Neoplasms (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 3
# of Trial APIs: 8